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The activation-induced deaminase (AID)/APOBEC cytidine deaminases participate in a
diversity of biological processes from the regulation of protein expression to embryonic
development and host defenses. In its classical role, AID mutates germline-encoded
sequences of B cell receptors, a key aspect of adaptive immunity, and APOBEC1, mutates
apoprotein B pre-mRNA, yielding two isoforms important for cellular function and plasma
lipid metabolism. Investigations over the last ten years have uncovered a role of the
APOBEC superfamily in intrinsic immunity against viruses and innate immunity against viral
infection by deamination and mutation of viral genomes. Further, discovery in the area of
human immunodeﬁciency virus (HIV) infection revealed that the HIV viral infectivity factor
protein interacts with APOBEC3G, targeting it for proteosomal degradation, overriding
its antiviral function. More recently, our and others’ work have uncovered that the
AID and APOBEC cytidine deaminase family members have an even more direct link
between activity against viral infection and induction and shaping of adaptive immunity than
previously thought, including that of antigen processing for cytotoxicT lymphocyte activity
and natural killer cell activation. Newly ascribed functions of these cytodine deaminases
will be discussed, including their newly identiﬁed roles in adaptive immunity, epigenetic
regulation, and cell differentiation. Herein this reviewwediscussAID andAPOBEC cytodine
deaminases as a link between innate and adaptive immunity uncovered by recent studies.
Keywords: restriction factors, CTL, HIV, correlate of protection, APOBEC1,APOBEC2,APOBEC3
INTRODUCTION
Higher eukaryotes have developed multiple strategies to coun-
teract viral infections. A ﬁrst line of defense is based on the
recognition of pathogen-associated molecular patterns (PAMPs)
such as viral replication intermediates that are molecules not
commonly found in uninfected host cells. PAMPs were origi-
nally deﬁned as molecular patterns speciﬁc to microbes, highly
conserved and required for microbial function, and thus, are self–
nonself discriminatingmolecules for higher eukaryotic organisms.
After the engagement of PAMPs with the subsequently identiﬁed
PAMP receptors, activation of a cascade of events leads to the
expression and, in some cases, secretion of antiviral molecules
and chemokines. Some of these molecules have been deﬁned as
“restriction factors” meaning host factors that have been evolu-
tionarily selected for based on their capacity to restrict microbial
infections. The receptors and effectors of this innate immunity
are germline-encoded and mediate key aspects of host defense.
However, viruses can also evade host defenses. It is the second arm
of the immune system, adaptive immunity, which provides ﬂexi-
ble antigen recognition based on somatic modiﬁcation of antigen
receptor genes in immune cells. This process involves selection of
immune cells that includes a step of deletion of antigen recep-
tors that are self-reactive, thus preventing autoimmunity, while
allowing adaptation to diverse pathogens and the establishment of
rapid and robust memory responses. There is evidence that com-
munication between innate and adaptive immunity is required to
clear pathogen infections that are otherwise deleterious to the host
(Iwasaki and Pillai, 2014). Innate and adaptive immunity are thus
considered interdependent.
Activation-induced deaminase (AID) and APOBEC (apolipo-
protein B mRNA editing enzyme, catalytic polypeptide-like)
enzymes are important in both innate and adaptive immune
responses. AID/APOBEC family members originate from a
large gene superfamily encoding for zinc-dependent deaminases
involved in the metabolism of purine and pyrimidine bases
(Conticello, 2008). The appearance of AID/APOBECs is thought
to be concurrent with the divergence of the vertebrate lin-
eage and the evolution of adaptive immunity (Conticello, 2008).
AID/APOBECs have a unique capacity to mutate DNA and/or
RNA of both host and pathogen as a result of their ability to
deaminate cytidine to uridine. This activity, referred to as nucleic
acid “editing,” is involved in various immune functions, including
restriction of viral replication, antigen presentation, and matura-
tion of host immune receptors. The structure of AID/APOBEC
proteins in relation with their editing activities has been recently
reviewed (Conticello et al., 2007; Desimmie et al., 2014). AID is
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thought to be the oldest member of the family and is essential
for antigen-driven B cell terminal differentiation and antibody
(Ab) afﬁnity maturation and diversiﬁcation (Muramatsu et al.,
2000). In humans, genetic deﬁciency of AID leads to Type-2
Hyper-IgM Syndrome (HIGM2), an immunodeﬁciency charac-
terized by the absence of antibodies other than the IgM class (Revy
et al., 2000). APOBEC1, the ﬁrst family member to be identiﬁed,
plays an important role in lipid metabolism due to its ability
to edit the apopoliprotein B (ApoB) pre-mRNA (Navaratnam
et al., 1993; Teng et al., 1993). APOBEC1 might also participate
in the restriction of viral infections (Ikeda et al., 2008; Gonza-
lez et al., 2009). APOBEC3s include seven members (A–C, DE,
and F–H) that are involved in the restriction of viral infection
and propagation affecting viruses such as human immunode-
ﬁciency virus (HIV), hepatitis C virus (HCV), and hepatitis B
virus (HBV). APOBEC2 and APOBEC4 functions remain poorly
understood although a role of APOBEC2 in embryogenesis has
been recently proposed (Vonica et al., 2010). Highlighting the
crucial role of AID/APOBECs in host defense, viruses have
developed mechanisms to interfere with AID/APOBEC biogen-
esis and/or functions, and in fact, APOBEC3G was originally
discovered due to its interaction with the HIV Vif protein
(Sheehy et al., 2002). Here, we will review the cellular func-
tions of AID/APOBEC family members and discuss recent work
investigating their contribution in innate and adaptive antiviral
immunity.
CELLULAR FUNCTIONS OF AID AND APOBEC FAMILY
MEMBERS
APOBEC1
In humans, APOBEC1 (A1) is uniquely expressed in the gas-
trointestinal tract and participates in plasma lipid metabolism.
In other species, such as mice, rats, horses, and dogs, A1 is
also present in the liver (Greeve et al., 1993). Until recently,
ApoB pre-mRNA was thought to be the single cellular target of
A1 (Teng et al., 1993). ApoB protein has two isoforms, ApoB-
100 and ApoB-48, encoded by a single gene in the liver and
small intestine, respectively. The shortest form, ApoB-48, is
the product of A1 editing activity and corresponds to the N-
terminal portion of ApoB. A1 converts a unique cytidine to
uridine (at position 6666 in Apo pre-mRNA) leading to a glu-
tamine to STOP codon substitution and ApoB-48 translation
(Navaratnam et al., 1993). ApoB-100 and ApoB-48 have differ-
ent biological properties and control the homeostasis of plasma
cholesterol. The editing activity of A1 is therefore an impor-
tant determinant for plasma concentrations of ApoB-containing
lipoproteins that are implicated in development of hyperlipi-
demia and atherosclerosis. Overexpression of A1 in the liver
of mice or rabbits reduces the concentration of low-density
lipoproteins. However, A1 overexpression also induces hepato-
cellular carcinoma in transgenic animals (Yamanaka et al., 1995),
most likely due to its capacity to edit DNA (Harris et al., 2002;
Petersen-Mahrt and Neuberger, 2003). A1 is indeed expressed
in the nucleus where ApoB pre-mRNA editing also occurs
(Lau et al., 1991).
More recently, using a transcriptome-wide RNA sequencing
screen comparing wild type and A1-deﬁcient mice, Papavasilou
et al. discovered that, in small intestine, many mRNA transcripts
other than apoB are edited by A1 (Rosenberg et al., 2011). The
targets of A1 are 3′-untranslated regions (3′ UTR) of mRNA
transcripts, suggesting additional roles for APOBEC1 beyond its
function in ApoB regulation.
APOBEC2
A2was cloned based on its sequence homologywithA1 (Liao et al.,
1999). A2 is well-conserved in the vertebrate lineages and can be
traced back to bony ﬁsh (Liao et al., 1999; Etard et al., 2010). Using
in vitromodels (e.g.,Escherichia coli),A2 has been shown to exhibit
intrinsic cytidine deaminase activity (Liao et al., 1999). Although
the A2 structure has been solved (Prochnow et al., 2007), its func-
tions remained elusive until recently. In humans, A2 is exclusively
expressed in heart and skeletal muscles (Liao et al., 1999). In mice,
A2 KO was reported to have no major effect on animal viability
and fertility (Mikl et al., 2005). This is in contrast to recent studies
that implicate A2 in embryonic development of ﬁsh and xenopus
(Etard et al., 2010; Pennings et al., 2010; Vonica et al., 2010). The
lack of A2 expression causes a dystrophic muscle phenotype in
zebraﬁsh embryos (Etard et al., 2010). A2 seems to inhibit TGFβ-
signaling, thus promoting muscle ﬁber differentiation both in vivo
(in zebraﬁsh and xenopus embryos) but also in vitro using a mam-
malianmyoblastic cell line (Vonica et al., 2010). Themechanismof
action and the targets of A2 action during embryogenesis are not
deﬁned, however, the ability of A2 (and other deaminases such as
AID) to deaminate methylated cystidines suggests a possible role
in epigenetic regulation (Rai et al., 2008).
AID
Activation-induced deaminase was cloned in a subtractive cDNA
library screen comparing activated and resting B cell lymphomas
(Muramatsu et al., 1999). AID is a key determinant in the gen-
eration of protective Ab-mediated adaptive immune responses.
The cytidine deaminase activity of AID initiates the introduction
of double stranded DNA breaks (DSB) in the immunoglobulin
heavy chain (IgH) gene locus allowing Ab diversiﬁcation, referred
to as class switch recombination (CSR; Muramatsu et al., 2000). In
addition, AID produces point mutations at the V(D)J region of Ig
loci, a mechanism referred to as somatic hypermutation, (SHM),
allowing B cell maturation (Muramatsu et al., 2000). These func-
tions require a rigorous targeting of AID activities to SHM and
CSR substrates (Kohli et al., 2010). Targeting might involve several
complementary mechanisms such as AID binding to replica-
tion protein A, a ssDNA-binding protein involved in DNA repair
(Basu et al., 2005), and/or association with a non-encoding RNA-
processing/degradation complex (Basu et al., 2011). The editing
activity of AID is not restricted to Ig loci and AID can act on a
wide spectrum of genomic targets in B cells (Yamane et al., 2011).
As a consequence, aberrant expression of AID promotes cancer
development in animal models and humans (Okazaki et al., 2007).
Dysregulated expressionofAID facilitatesDNAtranslocations that
require DSB such as c-myc/IgH found in Burkitt’s lymphoma and
c-myc/miR-142 found in B cell leukemia (Robbiani et al., 2008,
2009;Hashamet al., 2010). Constitutive or ubiquitousAID expres-
sion also leads to cancer development that is characterized by
point mutations in oncogenes as well as passenger mutations
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(thosemutations that do not contribute to cancer growth; Okazaki
et al., 2003). AID can therefore produce mutations in many genes
other than Ig genes. While most of these mutations are rapidly
repaired by the cellular DNA-repair machinery, those that are not
successfully repaired, can destabilize the genome of cells.
Although AID expression is at its highest levels in germi-
nal center B cells that undergo CSR and SHM, it is also found
in other cell types such as oocytes, embryonic stem (ES) cells,
and in estrogen-induced breast tissue (Fritz and Papavasiliou,
2010). The function of AID expression in these cells or tissues
remains to be elucidated. However, the study of lower vertebrates
including zebraﬁsh suggests that AID expression is involved in
epigenetic reprogramming of germ cells during early develop-
ment (Rai et al., 2008). Using an AID knockout mouse model,
Popp et al. (2010) revealed a role of AID in DNA demethyla-
tion during primordial germ cell reprogramming. DNA cytosine
methylation is associatedwith gene silencing and plays a key role in
development and genomic imprinting. The removal of 5-methyl
group on cytosine (5-mC) contributes to epigenetic reprogram-
ming required for the restoration of pluripotency of germ cells.
Several lines of evidence suggest that AID, but also A1 and A2,
might participate in this process of demethylation: AID and A1
can deaminate 5-methylcytosine in vitro and in E. coli (Morgan
et al., 2004), and germ cells from AID-deﬁcient mouse exhibit
a hypermethylation pattern (Popp et al., 2010). AID (and A2)
might contribute to the conversion of 5-mC to thymidine (T) later
replaced by cytosine (C) by the DNA-repair machinery (Rai et al.,
2008). In summary, AID function is not limited to Ab diversiﬁca-
tion, and evidence is accumulating to suggest a role in epigenetic
reprogramming.
APOBEC3s
Sheehy et al. (2002) initially discovered the ﬁrst family member
of APOBEC3, A3G, in ground-breaking studies with HIV infec-
tion. Since that original identiﬁcation, seven human A3 genes
clustered in tandem on chromosome 22 have been identiﬁed,
namely, A3A, A3B, A3C, A3DE, A3F, A3G, and A3H, which most
likely arose through gene duplication of a single-copy primordial
gene (Jarmuz et al., 2002). A3E was thought to be a pseudogene
but in fact, A3D and A3E form one unique protein (A3DE;
Dang et al., 2006). All A3 genes encode one or two conserved
zinc-coordinating deaminase domain (ZDD), which contains a
His/Cys-Xaa-Glu-Xaa23−28-Pro-Cys-Xaa2−4-Cys signature motif
[X denotes any amino acid (aa)]. Regions of human A3 mRNAs
share between 30 and 100% homology. Interestingly, depending
on the species, the A3 genes expanded and/or contracted. As a
result, A3 gene number ranges from one (mice, rats, pigs) to three
(cats) and six (horses; LaRue et al., 2008). In humans, A3 genes
are also highly polymorphic most likely due to the fact that they
have been under strong and continuing selective pressure dur-
ing primate evolution (Conticello et al., 2005; Henry et al., 2012).
As discussed later on in this review, A3 polymorphisms might
inﬂuence their speciﬁc antiviral activity.
A3 gene expression has been mainly documented in immune
cells and these results have been determined based on mRNA
levels in cells, using quantitative PCR (Koning et al., 2009;
Refsland et al., 2010). This approach is particularly difﬁcult since
A3 genes are highly homologous and polymorphic. Apart from
A3G and A3A, most antibodies to A3s are not very speciﬁc and
endogenous A3 proteins are often difﬁcult to detect. Nonethe-
less, several studies indicate a strong correlation between mRNA
level and protein expression (Refsland et al., 2010). There is a
general consensus that most A3s are highly expressed in T cells
[memory or naïve (Refsland et al., 2010)] but also in B cells and
phagocytic cells. A3A and A3B are predominantly expressed in
monocytes (Peng et al., 2007; Thielen et al., 2010) and B lympho-
cytes (Koning et al., 2009), respectively. A3G andA3F are expressed
in T cells, monocytes and dendritic cells (DC; Sheehy et al., 2002;
Pion et al., 2006; Peng et al., 2007; Pido-Lopez et al., 2007; Stopak
et al., 2007; Trapp et al., 2009). However, there is no consensus
regarding their relative abundance. A3s expression is not con-
ﬁned to immune cell populations, and are highly expressed in
human testis and ovary (A3G and A3F) (Koning et al., 2009) as
well as ES cells (A3B, A3C, A3DE, A3F, and A3G; Wissing et al.,
2011). A3G, A3F, A3B, and A3C are expressed in primary hepato-
cytes (Bonvin et al., 2006; Tanaka et al., 2006). The true breadth of
basal A3 expression in human tissues remains difﬁcult to estimate
as leukocytes inﬁltrate tissues and no suitable speciﬁc immuno-
histochemistry antibodies are presently available. Nevertheless,
different observations are in favor of a broad and constitutive
A3 expression proﬁle in human tissues. For instance, various can-
cer cell lines of non-immune origin - colorectal adenocarcinoma,
melanoma and lung carcinoma lines - express multiple human
A3s. It is possible that A3 expression is induced during onco-
genesis, but given the abundance of A3s in different cell types
it might also reﬂect their normal expression proﬁle prior to cell
transformation.
The cellular expression of A3s clearly indicates a role of A3s
in immunity. The broad distribution of A3s also points toward
a putative role in cellular maintenance. A3G and A3F localize
in cytoplamic microdomains and stress granules that are sites of
RNA storage and metabolism also called mRNA-processing bod-
ies (or P-bodies; Wichroski et al., 2006; Gallois-Montbrun et al.,
2008). Within P-bodies, A3G and A3F interact with effectors of
the RNA silencing machinery (such as Argonaute 1 and 2) and
translation suppressor (RCK/p54), suggesting that A3G-F par-
ticipate in RNA metabolism and fate determination (Wichroski
et al., 2006; Gallois-Montbrun et al., 2008). However, Phalora
et al. (2012) found no evidence that A3s participate in spe-
ciﬁc regulation of miRNA. In addition, the manipulation of
P-bodies using siRNA inhibition had no impact of A3 antivi-
ral functions and HIV replication (Phalora et al., 2012). The
reason why A3G and A3F localize to these P-bodies remains
unclear. More recently, a role of A3s in DNA catabolism has
also been proposed. Reminiscent of AID capacity to deami-
nate B cell genomes (during SHM and CSR), A3A edits host
nuclear and mitochondrial DNA leading to the introduction of
uridine (Suspene et al., 2011a). In the presence of functional
DNA repair machinery, most mutations are likely ﬁxed. In con-
trast, in uracil DNA-glycosylase (UNG)-deﬁcient cells, (UNGs are
enzymes required for excision of uracil bases), cytidine deami-
nations are readily detected using differential DNA-denaturation
PCR (3D-PCR) (Suspene et al., 2011a). The signiﬁcance of nuclear
DNA editing by A3A is rather enigmatic as hyperediting is
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synonymous with cell death and aberrant editing and/or repair
might contribute to tumorigenesis (Mussil et al., 2013). On the
other hand, phagocytic cells that express predominantly A3A
may use cytidine-deamination to mark foreign DNA for degra-
dation. In this model, the deamination of multiple cytidines
on foreign DNA might lead to uracil excision by UNG, creat-
ing nuclease-sensitive abasic sites, and subsequent degradation by
cellular nucleases (Stenglein et al., 2010). The nucleases involved
have not been characterized, but as discussed by Stenglein
et al. (2010) might include the IFN-inducible APEX or TREX1,
though a contribution of DNAse I and II cannot be ruled out.
This mechanism might represent an intrinsic immune defense
reminiscent of bacteria that evolved endonucleases to prevent
DNA transmission and bacteriophage infection (Stenglein et al.,
2010). To this regard it is interesting to note that A3A and
other A3s are induced upon inﬂammation (as described further,
below).
Much remains to be learned regarding the cellular functions of
A3s. Depending on cell type and tissue environment, A3s differ-
ently contribute to DNA/RNA deamination and their overarching
biological roles are still being elucidated.
AID, APOBEC1, AND APOBEC2 IN ANTIVIRAL IMMUNITY
APOBEC1
The sequence homology between A1 and A3G prompted
researchers to investigate a potential role of A1 in viral infec-
tion (Bishop et al., 2004a,b). In a pioneering work, Bishop et al.
(2004b) demonstrated that human A1 (hA1) incorporated into
HIV particles had no effect on HIV replication. In contrast,
rat A1 had a strong suppressive effect on HIV regardless of
Vif expression (Bishop et al., 2004b). Later work conﬁrmed that
in contrast to hA1, A1 from small animals (e.g., rabbit, ham-
ster, mouse) inhibited the replication of retroviruses such as SIV
(simian immunodeﬁciency virus), FIV (feline immunodeﬁciency
virus), and murine leukemia virus (MLV), and the activation of
autonomous retroelements in a deaminase-dependent manner,
thus suggesting a putative role for A1 in the restriction of viral
replication (Ikeda et al., 2008). The demonstration that A1 is a
restriction factor in the course of viral infections in natural hosts
came from the study of MLV and hepadnaviruses by the group of
Wain-Hobson andVartanian (Petit et al., 2009; Renard et al., 2010).
Analyzing viral sequences in HBV-infected chimpanzees, wood-
chucks chronically infected with the natural woodchuck hepatitis
virus (WHV) as well as ducks infected with duck hepatitis virus
(DHV), the authors provided evidence that A1 edits hepadnavi-
ral genomes and restricts replication in vivo (Renard et al., 2010).
Analyzing human serum from two HBV chronically infected car-
riers, the same group also suggested that A1 edits HBV genomes in
vivo (Gonzalez et al., 2009). These results were somehow surpris-
ing due to the fact that in humans A1 is not normally expressed
in the liver. However, viral infection might lead to ectopic expres-
sion of A1. During the course of viral infections, the inﬂuence
of IFN induction (or treatment) on A1 expression has not been
investigated thus far. Nonetheless, the function of A1 is most
likely not limited to the regulation of lipid metabolism. In ver-
tebrates, A1 likely participates in intrinsic defenses against some
viral infections.
APOBEC2
Though A2 exhibits deaminase activities (Liao et al., 1999), it has
not been assigned a role in the restriction of viral replication
thus far. However, it is interesting to note that in hepatocytes,
A2 expression is enhanced by pro-inﬂammatory cytokines such as
TNFα and IL-1β (Matsumoto et al., 2006). A2 contains functional
NF-kB response elements in the 5′ untranslated region, suggest-
ing a possible involvement in immune responses (Matsumoto
et al., 2006). In the tonsils of patients with Immunoglobulin A
nephropathy (IgAN) a disease characterized by IgA deposition to
glomerular mesangial cells and glomerulonephritis, A2 expres-
sion is up-regulated around B cell germinal centers (where B cells
undergo CSR and SHM with the “help”of follicular T cells). How-
ever, a direct role of A2 in IgAN pathology or IgA production has
not been established (Iio et al., 2010).
AID
As discussed earlier, AID is required for CSR and, as a result,
is critical for the generation of B cells that secrete Abs with
various effector functions and tissue distribution in the organ-
ism (Muramatsu et al., 2000). For instance, immunoglobulins
of the IgA isotype are found at the portal of pathogen entry
in the mucosa and can be transported across the epithelium to
neutralize pathogens. IgG is the principal isotype in the blood
and extracellular ﬂuid and is involved in pathogen neutraliza-
tion, opsonization, and complement activation. AID −/− mice
harbor a complete defect of CSR with a hyper-IgM phenotype
and present enlarged germinal centers containing activated B
cells (Muramatsu et al., 2000). In addition, AID involvement
in SHM allows the generation of B cells with the potential
to secrete Abs with higher afﬁnities (Imai et al., 2003). Inter-
estingly, mice carrying a mutated allele of AID with reduced
capacity to perform SHM but with normal amounts of CSR,
exhibit an impaired gut homeostasis and inefﬁcient mucosal
defenses (Wei et al., 2011). In humans, genetic deﬁciencies of
AID are responsible for the development of a rare immunode-
ﬁciency, HIGM2 (Revy et al., 2000). HIGM2 is characterized by
the absence of antibodies other than IgM and a profound sus-
ceptibility to bacterial infections (Revy et al., 2000). AID is there-
fore a key determinant in protective immunological responses,
and the most well-documented mechanism of this protection
is through the generation of protective Ab-mediated immune
responses.
The action of AID is not limited to B cell differentiation and
maturation as there is accumulating evidence thatAID contributes
to innate defenses against viruses. For example, HCV, Epstein-
Barr virus (EBV), and Kaposi’s sarcoma-associated herpesvirus
(KSHV) have been shown to induce AID expression in B cells
residing outside the germinal centers (Machida et al., 2004; Rosen-
berg and Papavasiliou, 2007; Bekerman et al., 2013). It is unclear
so far whether AID up-regulation is beneﬁcial or deleterious to
HCV and EBV, however, in the case of KSHV, AID has a direct
impact on viral ﬁtness by inhibiting lytic reactivation and by
reducing infectivity of virions. Further reinforcing the role of AID
in antiviral responses, KSHV encodes microRNAs that dampen
AID expression (Bekerman et al., 2013). Whether the deaminase
activity of AID is required for KSHV restriction [as described
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for A3G (see below)] remains to be determined. In hepatocytes,
AID expression also correlates with reduced susceptibility to HBV
infection (Watashi et al., 2013), a mechanism that might be depen-
dent on deamination of the HBV genome by AID (Liang et al.,
2013). AID might also participate in responses against transform-
ing retroviruses. AID-deﬁcient mice have been shown to be more
susceptible to Abelson murine leukemia virus (A-MuLV), a defec-
tive virus that causes pro-B cell leukemia in vivo (Gourzi et al.,
2006). In this case, the action of AID does not involve direct edit-
ing of the viral genome. Instead, AID might cause damage in the
host cell genome, resulting in cell cycle arrest and/or up-regulation
of stress-inducible factors, leading to natural killer (NK) cell acti-
vation and thus slower tumor growth (Gourzi et al., 2006). AID
expression also correlates with the induction of aberrant SHM
that might contribute to B cell transformation and tumorigenesis
(Machida et al., 2005; Epeldegui et al., 2007).
APOBEC3s AND ANTIVIRAL IMMUNITY
A3G was the ﬁrst member of APOBEC family to be assigned
a role in antiviral immunity by demonstration of its activity
against HIV infectivity (Sheehy et al., 2002). Since then, it has
been demonstrated that human A3 cytidine deaminases affect
the replication of a variety of viruses (Chiu and Greene, 2008)
and impact the activation of adaptive immunity (Casartelli et al.,
2010). A3G restricts the replication of retroviruses such as HIV,
Foamy virus (FV; Delebecque et al., 2006), human T-cell leukemia
virus type-1 (HTLV-1; Mahieux et al., 2005) as well as DNA
viruses such as HBV (Turelli et al., 2004; Suspene et al., 2005)
and also affects endogenous retroviruses (Esnault et al., 2005).
A3A, A3C, and A3H deaminate human papillomavirus (HPV)
genomes (Vartanian et al., 2008) and A3C acts on herpes viruses
[e.g., herpes simplex-1 (HSV-1) and EBV viruses (Suspene et al.,
2011b)]. HumanA3G also acts on viruses infecting rodents (MLV)
or avian species (Rous sarcoma virus and alpharetroviruses). A3
family members can play redundant roles in antiviral immunity
(Albin and Harris, 2010). For instance, A3G and A3F restrict HIV
and like A3C, A3G also acts on herpes viruses, although to a
lesser extent (Suspene et al., 2011b). Intrinsic speciﬁcities of A3
proteins, but also their tissue distribution and cellular expres-
sion levels most likely determine the impact of each A3 family
member on viral replication and on the activation of antiviral
immunity.
INTRINSIC ANTIVIRAL FUNCTION OF A3s
The characterization of mutant HIV defective for the accessory
protein Vif led to the discovery of A3G. Vif is essential for HIV-
1 replication in a variety of cells including primary human T
cells, monocytes, macrophages, DC and lymphoid T cell lines
such as CEM, HUT78, also called “non-permissive” cells. How-
ever,Vif is dispensable in“permissive” T cell lines such as CEM-SS
(a variant of CEM), Jurkat and supT1 cells [see for an in depth
review (Henriet et al., 2009)]. A subtractive cDNA library screen –
using CEM and CEM-SS T cell lines - led to the identiﬁcation of
humanA3G that is strongly expressed by non-permissive CEM-SS
cells (Sheehy et al., 2002). In non-permissive cells, A3G is incor-
porated into budding virions and acts on HIV replication in a
post-fusion event in newly infected cells (Figure 1). Transfection
of A3G in permissive cells leads to abrogated replication of Vif-
deﬁcient HIV (HIV Vif) (Sheehy et al., 2002) and sequencing of
HIV Vif DNA revealed a hypermutated pattern with enriched G
to A transitions (Lecossier et al., 2003), strongly suggesting that
A3G deaminase activity is required for the restriction of HIV
replication (Zhang et al., 2003). It is now established that Vif
counteracts the antiviral functions of A3G and other A3 family
members such as A3F and a certain allele of A3H (Henriet et al.,
2009). The action of Vif on A3s has been extensively reviewed
(Henriet et al., 2009), but in sum, in infected cells, Vif targets
A3G for proteasomal degradation, reducing the amount of A3G
incorporated into budding virions (Figure 1). Indeed, as a post-
fusion event, A3G catalyzes cytosine to uracil deamination on the
nascentminus DNAstrandof theHIV reverse transcribed genome
(Harris et al., 2003; Mangeat et al., 2003; Yu et al., 2004). The pres-
ence of uracil on the minus strand of HIV DNA might target
HIV DNA for degradation by the cellular DNA repair machinery
thus reducing viral replication (Mariani et al., 2003). As exem-
pliﬁed by the existence of hyper-edited sequences retrieved from
HIV proviruses in vivo (Kieffer et al., 2005), the action of Vif on
A3G incorporation/degradation is not absolute and deaminations
also lead to G to A transitions in HIV DNA (Harris et al., 2003;
Lecossier et al., 2003; Mangeat et al., 2003; Yu et al., 2004). Editing
patterns are dominated by GG to AG hypermutations leading to
a high frequency of amino acid substitutions and to the introduc-
tion of premature STOP codons (Vartanian et al., 1991). These
crippled proviruses express aberrant (i.e., misfolded or trun-
cated) viral proteins that are unable to produce infectious particles
(Simm et al., 1995).
Shortly after the discovery of A3G, A3F was shown to restrict
HIV replication. A3G and A3F editing is not random. A3G
and A3F preferentially introduce mutations in TGG or TGA
sequences, respectively. There is a lack of consensus on the abil-
ity of other A3 family members to edit HIV [see for a review
(Albin and Harris, 2010)]. For instance, over-expression of A3B
and A3DE exerts anti-HIV activity in a single cycle assay but
insigniﬁcant antiviral activity in a spreading infection system
(Hache et al., 2008). A3D, F, G, and H but not A3B, C, and DE
restrict infection of human CD4+ T lymphocytes by Vif-deﬁcient
viruses (Hultquist et al., 2011). A3DE restricts HIV replication
in macrophages but to a lower extent than A3G (Chaipan et al.,
2013). In myeloid cells, APOBEC3A blocks early steps of reverse
transcription but acts when expressed in the target cell of infection
(Berger et al., 2011).
There is a general agreement that cytidine deamination plays an
important role in the capacity of A3s to restrict viral replication
(Schumacher et al., 2008; Browne et al., 2009). However, several
reports also suggest that A3G and A3F restrict viral replication to
a signiﬁcant extent through deaminase-independent mechanisms
(Newman et al., 2005). A3G and A3F affect reverse transcription
priming and extension (Mangeat et al., 2003; Mariani et al., 2003;
Guo et al., 2006; Anderson and Hope, 2008; Malim, 2009; Wang
et al., 2012; Gillick et al., 2013) and HIV DNA integration into
the host genome (Luo et al., 2007; Mbisa et al., 2007; Vetter and
D’Aquila, 2009). As proposed by Henriet et al. (2009) interference
of A3G and A3F with the viral core assembly might be responsible
for these deaminase-independent impairments of HIV replication.
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FIGURE 1 | APOBEC3G links innate/intrinsic immunity with adaptive
cellular immunity. A3G is expressed at various levels in human
immunodeﬁciency virus (HIV) infected cells and can be induced upon viral
sensing by Toll-like receptors (TLR), triggering of CD40 or CCR5 and IFN
production (left). A3G is incorporated in budding virions and exerts its
antiviral activities in newly infected cells (right). During reverse
transcription, A3G catalyzes cytosine to uracil deaminations on the nascent
minus DNA strand of HIV. The presence of uracil and the expression of
HIV Vpr recruit the cellular DNA repair machinery (UNG2, right middle)
leading to either HIV DNA restoration or degradation, the latter reducing
viral replication. The cellular DNA-repair machinery trying to cope with
uracil-rich HIV DNA also activates the DNA-damage- and stress–response
pathways leading to the up-regulation of activating natural killer (NK) cell
ligands (NKG2D ligands) and killing of infected cells (right middle). In
addition, deaminations lead to G to A transitions in HIV DNA leading to
the integration of proviruses with a high frequency of amino acid
substitutions and/or premature STOP codons. These proviruses express
aberrant viral proteins that are unable to produce infectious particles.
Infected cells can use these misfolded or truncated viral proteins (called
DRiPs, defective ribosomal products) to generate MHC-I epitopes leading
to activation of anti-HIV cytotoxic T lymphocyte (CTL) responses (right
upper). However, in infected cells, Vif counteracts the antiviral functions of
A3G by targeting newly synthetized A3G for proteasomal degradation, thus
reducing the amount of A3G incorporated into budding virions (left) and
facilitating HIV replication in newly infected cells (right bottom). Viral
replication is therefore the result of a balance between anti-viral innate
and adaptive (cellular) immunity promoted by A3G and Vif-mediated
escape mechanisms developed by HIV.
The balance of editing and non-editing-dependent effects of A3G
and A3F varies depending on the experimental system and might
be affected by their cellular expression levels (Miyagi et al., 2007;
Knoepfel et al., 2008; Browne et al., 2009).
INDUCTION OF A3 EXPRESSION
In humans, A3s are not only expressed in a variety of tissues,
but their expression is also induced by mediators of inﬂamma-
tion, possibly reﬂecting their role as a ﬁrst line of defense against
invading viruses (Figure 1). IFN-α was reported to enhance A3G
andA3A expression inmonocytes andmacrophages. IFN-γ and -β
also induceA3G up-regulation in macrophages (Sarkis et al., 2006;
Peng et al., 2007; Stopak et al., 2007; Koning et al., 2009; Refsland
et al., 2010; Berger et al., 2011). IFN-α secreted by plasmacytoid
dendritic cells (pDC) enhances the expression of A3A, A3C, A3G,
and A3F within pDC, indicating that pDC might be armed against
viral infection by an autocrine IFN-α loop (Wang et al., 2008).
Pathogen sensors such as Toll-like receptors (TLR) also inﬂuence
A3 gene expression. TLR-3 stimulation by the double stranded
RNA analog [poly(I:C)] induces type I IFN responses in DC
and subsequent A3G expression (Trapp et al., 2009). Overall, the
induction of DC maturation using stimuli such as LPS (a TLR-4
ligand), CCR5 and CD40 ligands correlates with the up-regulation
of A3G (Pion et al., 2006; Pido-Lopez et al., 2007; Stopak et al.,
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2007). The effect of IFN-α on A3 expression in primary CD4+
T cells is controversial, but in most reports no induction was
observed (Rose et al., 2005; Chen et al., 2006; Sarkis et al., 2006;
Stopak et al., 2007; Ying et al., 2007; Koning et al., 2009; Refs-
land et al., 2010). In contrast, IL-2, IL-7, IL-15, and IL-27 and
mitogens such as phytohemagglutinin (PHA) and phorbol myris-
tate acetate (PMA) induced modest and strong activation of A3G
expression, respectively, (Stopak et al., 2007). Combined with IL-
2, PHA induces expression of all A3s except A3A (Greenwell-Wild
et al., 2009; Koning et al., 2009; Refsland et al., 2010). Triggering
of the T cell receptor (TcR) also induces A3G expression in effec-
tor memory T cells and interferes with HIV replication in vitro
(Pido-Lopez et al., 2009).
The induction of A3 expression is not limited to immune
cells. IFN-α secretion, for instance, can induce A3G, A3F, and
A3B expression in hepatocytes (Bonvin et al., 2006; Sarkis et al.,
2006; Tanaka et al., 2006). In contrast, other factors reduce A3
protein expression. The nerve growth factor (NGF), an essential
factor for survival and activation of monocytes/macrophages, is
released by HIV infected macrophages and dampens the synthe-
sis of A3G, overriding the IFN-γ-induced upregulation of A3G
(Souza et al., 2011).
Overall, the transcriptional regulation of A3 genes seems to play
a major role in A3-dependent defenses against viruses. Remark-
ably, following mucosal immunization of nonhuman primates,
two studies reported the up-regulation of A3G in CCR5+ CD4+
memory T cells (Wang et al., 2009) as well as in mucosal DC and
CD14+ cells (Sui et al., 2010), all potential cellular targets of HIV
replication. A3G mRNA upregulation was maintained over sev-
eral weeks after immunization and upon challenge with SIV, and
correlated inversely with viral loads and positively with a better
preservation of CD4+ T cells in the gut (Sui et al., 2010). These
studies strongly suggest that A3G provides an antiviral effect in
vivo. They also demonstrate that mucosal immunization triggers
an innate signature that promotes adaptive immune responses.
The exact mechanism underlying vaccine-induced A3G express-
sion with protection from SIV infection is not clear. As observed
in the murine model of Friend retrovirus (FV) infection (San-
tiago et al., 2010), by limiting early viral replication, A3G might
delay virus-induced immune dysfunction and thus might favor
the establishment of humoral [e.g., generation of FV-neutralizing
antibodies (Santiago et al., 2010)] and cellular immunity.
A ROLE OF A3G IN THE ACTIVATION OF CELLULAR AND
ADAPTIVE IMMUNITY
There is growing evidence that A3G bridges intrinsic and cel-
lular immunity as is the case with AID, that shapes the Ab
repertoire, blocks virus-induced cancer by inducing cell cycle
arrest and activates NK cells (Gourzi et al., 2006). A3G has
been implicated in enhancing NK-cell killing of HIV-infected T
cells (Norman et al., 2011). This process requires A3G-editing
of HIV DNA (Norman et al., 2011). In this study, the authors
propose that the cellular DNA-repair machinery activates DNA-
damage- and stress–response pathways in response to uracil-
edited HIV DNA, leading to the up-regulation of activating
NK cell ligands (NKG2D ligands) and killing of HIV infected
cells. The authors also implicate the HIV Vpr protein and its
capacity to recruit the DNA-repair machinery as a key factor
in NKG2D ligand expression. In contrast, HIV Vif counter-
acts the action of A3G and the NK cell-mediated elimination
of HIV-infected cells (Norman et al., 2011). Interestingly, in the
work of Norman et al. (2011), cytoplasmic A3G (expressed by
the target cell) seems responsible for HIV editing and thus NK
cell recognition. Cytoplasmic A3G has been shown to impact
HIV genome integration but has not been assigned a role in
HIV genome editing, to our knowledge (Vetter and D’Aquila,
2009). Whether the accumulation of unintegrated HIV genomes
or the editing of HIV genomes per se might be responsible
for the induction of stress responses and thus NK cell recogni-
tion remains to be clariﬁed (Norman et al., 2011). Nonetheless,
this study suggests that A3G antiviral functions allow trigger-
ing of danger signals that, in turn, activate effectors of cellular
immunity.
A3G-mediated editing also contributes to the activation of
effectors of adaptive immunity (Casartelli et al., 2010), namely,
CD8+ cytotoxic T cells (CTLs). CTLs, whose function is critical
in the control of HIV infection, are triggered by viral peptides pre-
sented by MHC class-I molecules on the surface of infected cells.
These antigenic peptides originate from proteasomal degradation
of native viral proteins and of defective/abortive proteins gener-
ated in the course of translation (Yewdell and Nicchitta, 2006). We
made the assumption that hyper-edited proviruses that express
aberrant – misfolded or truncated – viral proteins might represent
a source of HIV antigens. We demonstrated that A3G enhances
cytotoxic T lymphocyte (CTL) recognition of HIV-infected cells
(Casartelli et al., 2010). This process requires A3G-editing of HIV
DNA as editing–deﬁcient A3G mutants failed to promote CTL
activation. MimickingA3G-editing,we also showed that truncated
HIV proteins represent a major source of HIV antigen for CTL
activation (Casartelli et al., 2010). However, and as expected,Vif as
well as Nef (that down-regulated MHC-I expression) counteracts
the action of A3G in antigen generation. Therefore, recognition
of HIV-infected cells by CTLs results from a balance between
the efﬁcacy of antigen generation enhanced by A3G editing and
the immune-escape mechanisms mediated by the virus. Over-
all, these studies demonstrate that A3G-mediated viral restriction
contributes to the immunogenicity of HIV-infected cells and
to NK cell as well as CTL activation, thus linking innate and
adaptive immunity (Figure 1). Whether other APOBEC3 fam-
ily members enhance NK cell and CTL activation remains to be
determined.
IN VIVO INTERACTIONS OF APOBEC3s AND HIV-1
A3s AND CORRELATES OF DISEASE PROGRESSION
Accumulating evidence suggests that A3s play an important role
in limiting viral replication in vivo. APOBEC3 genes have been
subject to strong positive selection throughout the history of
primate evolution (Sawyer et al., 2004). In persistent HBV infec-
tion, A3 polymorphisms seem to impact liver disease progression
and viral loads (Ezzikouri et al., 2013). In the course of HIV
infection, A3G plays a critical role in limiting the viral reser-
voir. A major barrier to an effective cure of HIV infection is
the maintenance of a latent viral reservoir in the memory CD4
T cell compartment within HIV-infected, successfully treated
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(ST) individuals (Chomont et al., 2009). Examining the state
of the latent proviruses in these cells from ST subjects, sev-
eral studies have established that approximately 30% of HIV
proviruses that can not be reactivated in vitro carry the hall-
mark of A3G editing (Ho et al., 2013). Thus, in vivo, A3G
plays a signiﬁcant role in rendering the persistent viral reser-
voir defective, inactive, or “non-inducible.” However, whether
A3G antiviral functions play a critical role in HIV progression
is less clear (Albin and Harris, 2010). Analyzing the mutation
patterns of proviral sequences isolated from various cohorts,
several studies showed a correlation between hypermutation
mediated by either A3G or A3F and reduced viral loads (Pace
et al., 2006; Vazquez-Perez et al., 2009; Kourteva et al., 2012)
or increased CD4 counts (Land et al., 2008). Consistent with
these observations, proviral sequences from HIV-infected long-
term non-progressors (LTNP) or viral controllers (elite con-
trollers) seem to harbor an elevated level of hypermutation
compared to antiretroviral therapy (ART)-treated or naïve non-
controllers (Kourteva et al., 2012; Eyzaguirre et al., 2013). In
contrast, others observed no correlation between hypermuta-
tion with markers of disease progression (Piantadosi et al., 2009;
De Maio et al., 2012) nor with the clinical status such as being
elite controllers (Gandhi et al., 2008). These contrasting results
might be due to technical issues or the size of the cohorts
studied.
However, owing to the editing-independent antiviral activities
of A3s, other studies analyzed the association betweenA3G orA3F
expression levels (mostly at the mRNA level) and markers of dis-
ease progression. But, again, there is no clear-cut answer. Some
studies observed that the mRNA levels of A3G correlate positively
with CD4 cell counts (Jin et al., 2005; Vazquez-Perez et al., 2009;
Zhao et al., 2010) and inversely with viremia (Jin et al., 2005; Zhao
et al., 2010; Kourteva et al., 2012) or the viral set point (that is
predictive of disease progression; Ulenga et al., 2008). In addition,
exposed uninfected individuals showed greater A3G mRNA lev-
els (Biasin et al., 2007; Vazquez-Perez et al., 2009) and controllers
with high A3G protein expression in CD4 T cells seem to harbor
fewer HIV proviruses (De Pasquale et al., 2013). However, others
observed no correlation between mRNA expression levels of either
A3G or A3F and markers of disease progression (Cho et al., 2006;
Amoedo et al., 2011). Also, during primary infection no associa-
tion between A3G expression and viral loads was observed (Reddy
et al., 2010) and others did not ﬁnd greater A3G mRNA levels in
exposed uninfected individuals (Mous et al., 2012). Larger cohort
studies analyzing side-by-side hypermutation patterns and expres-
sion levels of all A3 family members might help in establishing a
correlation with clinical parameters.
However, variants of A3 at the genetic levels might also account
for limiting disease progression. In a pioneering study,An et al (An
et al., 2004) identiﬁed a variety of A3G polymorphisms within
introns and exons that correlate with clinical parameters. A3G
H186R identiﬁed in this study was shown in various cohort stud-
ies to correlate with disease progression (An et al., 2004; Reddy
et al., 2010; Singh et al., 2013). The variant H186R of A3G is also
associated with low CD4 counts (Bunupuradah et al., 2012) and
a polymorphism within an A3G intron (C40693T) was shown to
correlate with increased risk of infection (Valcke et al., 2006).
Othermembers of theAPOBEC3 family present commonpoly-
morphisms such as A3H and A3B. In contrast to A3G, A3H
anti-HIV activity is strongly inﬂuenced by its polymorphisms
(Ooms et al., 2013) with some speciﬁc alleles associated with lower
viremia (Gourraud et al., 2011). A3B is deleted in ∼20% of the
world’s population. An early study based on a large number of
U.S. patients showed that a homozygous deletion of A3B was
associated with increased susceptibility to HIV acquisition and
progression to AIDS (An et al., 2009). However, a more recent
study on Japanese individuals did not observe such a correlation
(Imahashi et al., 2014).
Whether A3 family members inﬂuence viral transmission and
disease progression remains an open question. In addition, the
underlying mechanisms are not clear, such as whetherA3G H186R
and C40693T differentially impact HIV replication, and to date,
this has not been experimentally demonstrated.
A3-MEDIATED EDITING AND VIRAL
DIVERSIFICATION/ADAPTATION
A3 antiviral activities, and, in particular, editing, might also facil-
itate HIV survival by introducing sub-lethal mutations that, in
turn, favor HIV diversiﬁcation and adaptation to ART and/or
immune responses. The action of Vif on A3 degradation is not
absolute thus allowing A3 incorporation and subsequent sub-
lethal editing (Sadler et al., 2010). Evidence of this phenomenon
was provided by the demonstration that a Vif allele carrying the
K22H mutation, less effective in counteracting A3-mediated edit-
ing,was prevalent in a cohort of ART-treated patients experiencing
virological failure (Fourati et al., 2010). In this study, several
drug resistance mutations in reverse transcriptase (RT) and in
the protease, were signiﬁcantly more common in patients har-
boring elevated levels of K22H-mutated viruses (Fourati et al.,
2010). The expression of K22H-Vif might favor adaptation to
antiviral drugs by allowing residual A3-mediated deamination
and introduction of mutations into HIV genome. A parallel
might be drawn here with hypermutator strains of bacteria that
adapt more rapidly to antibiotic. These hypermutator strains
of bacteria have mutations in genes affecting DNA repair and
replication ﬁdelity and exhibit elevated mutation rates (Wood-
ford and Ellington, 2007). Cytidine deamination might directly
promote mutations that generate resistance to drugs. For exam-
ple, the common M184V mutation of RT that causes resistance
to 3TC is located in an A3G editing hotspot and is produced
in vitro by A3G during HIV replication (Mulder et al., 2008;
Kim et al., 2010). A3G-mediated sub-lethal editing might also
favor mutations within sequences encoding HIV CTL epitopes
thus allowing the virus to escape CTL-recognition (Wood et al.,
2009; Monajemi et al., 2014). In contrast, cytidine deamina-
tion outside HIV CTL epitopes (especially downstream of the
epitope) might favor the expression of unstable aberrant or
truncated HIV proteins and thus HIV-speciﬁc CTL activation
(Casartelli et al., 2010).
On the other hand, A3G-editing at physiological levels might
be simply lethal to HIV. Armitage et al. (2012) showed, in an
in vitro study, that even a single A3G molecule within one
HIV particle is likely to cause extensive and inactivating lev-
els of HIV hypermutation (Armitage et al., 2012). The authors
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suggest that A3-mediated hypermutation might be a discrete
“all or nothing” phenomenon (Armitage et al., 2012). The over-
all impact of A3-mediated hypermutation on HIV survival and
adaptation might also vary depending on the anatomical site
(Fourati et al., 2014).
CONCLUDING REMARKS
The AID-APOBEC family members evolved from a family of
cytidine deaminases to ﬁght viral infection. They constitute an
important arm of innate immunity by restricting replication and
spread of a plethora of viral infections. Although establishing cor-
relates of disease progression with hypermutation or expression
levels as a surrogate of APOBEC antiviral functions has proven to
be complex in HIV infection, in vivo defective proviral sequences
clearly bear the hallmark of APOBEC editing. AID-APOBEC fam-
ily members also participate in long-term adaptive immunity to
viral infections. AID is critical for the generation of B cells that
secrete high afﬁnity Abs with various effector functions. A3G
contributes in activating NK cell and CTL responses leading to
the elimination of HIV-infected cells. Remarkably, the expression
levels of AID-APOBEC family members are increased upon the
sensing of infection and a tight regulation is required to avoid
deleterious editing of host genomes.
Manipulating AID-APOBECs with drugs might constitute
promising approaches to ﬁght infections. Strategies have been
proposed to increase A3 expression to favor encapsidation within
viral particles thus overriding the antagonistic activity of Vif
and controlling HIV-1 infection [reviewed in (Albin and Har-
ris, 2010)]. The antiviral properties of Vif inhibitors are currently
being evaluated (Ali et al., 2012). A3G expression can be manipu-
lated either by limiting its proteasomal degradation (Ejima et al.,
2011), or exacerbated to supraphysiologic levels. Treatment of
HIV/HCV co-infected patients with IFN-α, for instance, increases
mRNA expression of A3G/F and correlates with the degree of
HIV hypermutation (Pillai et al., 2012). Upon vaccination, A3
expresssion can also be induced promoting adaptive immune
responses (Wang et al., 2009; Sui et al., 2010). Taken together,
these ﬁndings further highlight the complex and intriguing inter-
actions of AID-APOBEC family members with the immune
system.
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